Siamak Yousefi, None;
Michael Goldbaum, None;
Ehsan Shahrian Varnousfaderani, None;
Linda Zangwill, Carl Zeiss Meditec Inc (F), Carl Zeiss Meditec Inc (R), Heidelberg Engineering GmbH (F), Optovue Inc. (F), Optovue Inc. (R), Quark (F), Topcon Medical Systems Inc. (F);
Felipe Medeiros, Alcon (C), Allergan (F), Allergan (C), Ametek (F), Ametek (C), Bausch+Lomb (F), Carl-Zeiss Meditec (F), Carl-Zeiss Meditec (C), Carl Zeiss Meditec Inc (R), Heidelberg Engineering (C), Heidelberg Engineering GmbH (F), Sensimed (F), Topcon (F);
Robert Weinreb, Alcon (C), Allergan (C), Amatek (C), Bausch+Lomb (C), Carl Zeiss Meditec (C), Carl Zeiss Meditec (F), Carl Zeiss Meditec (R), Forsight (C), Genentech (F), Heidelberg Engineering (F), Konan (F), National Eye Institute (F), Neurovision (F), Optovue (F), Quark (F), Reichert (F), Tomey (F), Topcon (C), Topcon (F), Valeant (C);
Christopher Girkin, Carl Zeiss Meditech, Inc. (F), EyeSight Foundation of Alabama (F), Heidelberg Engineering, GmbH (F), National Eye Institute (F), Research to Prevent Blindness (F), SOLX (F);
Jeffrey Liebmann, Allergan, Inc. (F), Bausch & Lomb, Inc. (F), Bausch & Lomb, Inc. (C), Carl Zeiss Meditech, Inc (C), Carl Zeiss Meditech, Inc (F), Diopysis, inc. (C), Diopysis, inc. (E), Heidelberg Engineering, GmbH (C), Heidelberg Engineering, GmbH (F), Merz Phamaceuticals, Inc. (C), National Eye Institute (F), New York Glaucoma Research Institute (F), Optovue (F), Quark Pharmaceuticals, Inc. (C), Reichert, Inc. (C), Sensimed, Inc. (C), SOLX, Inc. (E), Sustained Nano System (E), Topcon, Inc. (F), Valeant Pharmaceutiicals, Inc. (C);
Christopher Bowd, None